Benzinga · Feb 24, 2026
OR
NASDAQ · ORIC
ORIC Pharmaceuticals, Inc.
Healthcare · Biotechnology
$12.50
Down-$0.12 (-0.95%)
Updated Sep 10, 2026, 8:35 AM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 944.68M
- P/E ratio
- -7.1
- Dividend yield
- 0.00%
- 52-week range
- $7.23 – $14.93
- Volume
- 1.67M
- Avg. volume
- 1.39M
Price performance
ORIC price history
1M range · 20 trading sessions · Daily adjusted prices
ORIC closed at $12.50 after 20 trading sessions, down 9.09% for the selected period.
- Last close
- $12.50
- Period change
- -9.09%
- Period low
- $12.50
- Period high
- $14.65
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $12.50 | $13.00 | $12.31 | $12.50 | 1.67M |
| Sep 8, 2026 | $12.67 | $12.87 | $12.54 | $12.62 | 955.4K |
| Sep 4, 2026 | $12.51 | $12.99 | $12.51 | $12.86 | 991.45K |
| Sep 3, 2026 | $13.17 | $13.41 | $12.59 | $12.74 | 916.44K |
| Sep 2, 2026 | $12.97 | $13.53 | $12.825 | $13.13 | 1.55M |
| Sep 1, 2026 | $12.82 | $13.06 | $12.77 | $12.89 | 646.37K |
| Aug 31, 2026 | $13.18 | $13.18 | $12.67 | $12.99 | 1.16M |
| Aug 28, 2026 | $13.59 | $13.925 | $13.20 | $13.24 | 765.43K |
| Aug 27, 2026 | $13.96 | $14.25 | $13.65 | $13.74 | 1.06M |
| Aug 26, 2026 | $13.74 | $13.97 | $13.48 | $13.91 | 1.12M |
| Aug 25, 2026 | $13.71 | $14.15 | $13.52 | $13.83 | 1.17M |
| Aug 24, 2026 | $14.16 | $14.52 | $13.44 | $13.46 | 1.11M |
| Aug 21, 2026 | $14.00 | $14.34 | $13.805 | $14.20 | 970.49K |
| Aug 20, 2026 | $14.32 | $14.515 | $13.7724 | $13.88 | 1.18M |
| Aug 19, 2026 | $14.20 | $14.68 | $14.09 | $14.65 | 1.39M |
| Aug 18, 2026 | $13.27 | $14.02 | $13.1183 | $13.92 | 948.88K |
| Aug 17, 2026 | $13.76 | $13.80 | $13.18 | $13.38 | 1.15M |
| Aug 14, 2026 | $13.63 | $13.90 | $13.40 | $13.87 | 828.63K |
| Aug 13, 2026 | $13.89 | $14.00 | $13.425 | $13.72 | 1.05M |
| Aug 12, 2026 | $13.72 | $13.985 | $13.45 | $13.75 | 1.15M |
Latest ORIC news
The latest Smart Investors Daily articles mentioning ORIC.
Stock researchCompany · Overview
ORIC research
Overview
Company profile and research snapshot.
Company profile
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $22.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 10, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 8, 2026 | HC Wainwright & Co. | Buy | — |
| May 5, 2026 | Citigroup | Buy | — |
| Apr 2, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 1, 2026 | Wedbush | Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 24, 2026
Citigroup Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $17
Citigroup analyst Yigal Nochomovitz maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $16 to $17.
Benzinga · Feb 24, 2026
HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $25
HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $23 to $25.
Benzinga · Feb 24, 2026
Wedbush Reiterates Outperform on ORIC Pharmaceuticals, Maintains $20 Price Target
Wedbush analyst David Nierengarten reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and maintains $20 price target.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
